BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 15604238)

  • 21. Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations.
    Christiansen DH; Desta F; Andersen MK; Pedersen-Bjergaard J
    Genes Chromosomes Cancer; 2007 Jun; 46(6):517-21. PubMed ID: 17330262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications.
    Lee WH; Raas-Rotschild A; Miteva MA; Bolasco G; Rein A; Gillis D; Vidaud D; Vidaud M; Villoutreix BO; Parfait B
    Proteins; 2005 Jan; 58(1):7-13. PubMed ID: 15521065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of PTPN11 are rare in adult myeloid malignancies.
    Hugues L; Cavé H; Philippe N; Pereira S; Fenaux P; Preudhomme C
    Haematologica; 2005 Jun; 90(6):853-4. PubMed ID: 15951301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
    Easton JB; Royer AR; Middlemas DS
    J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel PTPN11 mutation in LEOPARD syndrome.
    Conti E; Dottorini T; Sarkozy A; Tiller GE; Esposito G; Pizzuti A; Dallapiccola B
    Hum Mutat; 2003 Jun; 21(6):654. PubMed ID: 14961557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
    Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
    Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The tyrosine phosphatase Shp2 in development and cancer.
    Grossmann KS; Rosário M; Birchmeier C; Birchmeier W
    Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
    Binder G
    Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetics and variation in phenotype in Noonan syndrome.
    Jongmans M; Otten B; Noordam K; van der Burgt I
    Horm Res; 2004; 62 Suppl 3():56-9. PubMed ID: 15539800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
    Sznajer Y; Keren B; Baumann C; Pereira S; Alberti C; Elion J; Cavé H; Verloes A
    Pediatrics; 2007 Jun; 119(6):e1325-31. PubMed ID: 17515436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline KRAS mutations cause Noonan syndrome.
    Schubbert S; Zenker M; Rowe SL; Böll S; Klein C; Bollag G; van der Burgt I; Musante L; Kalscheuer V; Wehner LE; Nguyen H; West B; Zhang KY; Sistermans E; Rauch A; Niemeyer CM; Shannon K; Kratz CP
    Nat Genet; 2006 Mar; 38(3):331-6. PubMed ID: 16474405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel PTPN11 gene mutation in a patient with LEOPARD Syndrome.
    Du-Thanh A; Cave H; Bessis D; Puso C; Guilhou JJ; Dereure O
    Arch Dermatol; 2007 Sep; 143(9):1210-1. PubMed ID: 17875892
    [No Abstract]   [Full Text] [Related]  

  • 33. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome.
    Musante L; Kehl HG; Majewski F; Meinecke P; Schweiger S; Gillessen-Kaesbach G; Wieczorek D; Hinkel GK; Tinschert S; Hoeltzenbein M; Ropers HH; Kalscheuer VM
    Eur J Hum Genet; 2003 Feb; 11(2):201-6. PubMed ID: 12634870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
    Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
    Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
    Matozaki T; Murata Y; Saito Y; Okazawa H; Ohnishi H
    Cancer Sci; 2009 Oct; 100(10):1786-93. PubMed ID: 19622105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel mitochondrial DNA mutations implicated in Noonan syndrome.
    Dhandapany PS; Sadayappan S; Vanniarajan A; Karthikeyan B; Nagaraj C; Gowrishankar K; Selvam GS; Singh L; Thangaraj K
    Int J Cardiol; 2007 Aug; 120(2):284-5. PubMed ID: 17092585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning.
    Schollen E; Matthijs G; Gewillig M; Fryns JP; Legius E
    Eur J Hum Genet; 2003 Jan; 11(1):85-8. PubMed ID: 12529711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mild variable Noonan syndrome in a family with a novel PTPN11 mutation.
    Zenker M; Voss E; Reis A
    Eur J Med Genet; 2007; 50(1):43-7. PubMed ID: 17052965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilocytic astrocytoma in a child with Noonan syndrome.
    Schuettpelz LG; McDonald S; Whitesell K; Desruisseau DM; Grange DK; Gurnett CA; Wilson DB
    Pediatr Blood Cancer; 2009 Dec; 53(6):1147-9. PubMed ID: 19621452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
    Ogata T; Yoshida R
    Pediatr Endocrinol Rev; 2005 Jun; 2(4):669-74. PubMed ID: 16208280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.